Hudson Bay Capital Management LP Sells 31,367 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Hudson Bay Capital Management LP reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 33,791 shares of the biopharmaceutical company’s stock after selling 31,367 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Regeneron Pharmaceuticals were worth $19,000,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Salomon & Ludwin LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $31,000. Caitlin John LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $34,000. Traub Capital Management LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $38,000. Finally, Berbice Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 over the last 90 days. 7.02% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on REGN shares. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price objective for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $744.12 on Thursday. The business has a 50-day moving average price of $767.89 and a two-hundred day moving average price of $698.50. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company has a market cap of $78.67 billion, a P/E ratio of 17.90, a PEG ratio of 2.04 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the company earned $12.07 EPS. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.